Cephalon finalises $425 million settlement on off-label probe
This article was originally published in Scrip
Executive Summary
Cephalonhas finalised a previously announced $425 million payout to settle a federal probe of its marketing of three products for unapproved uses. The allegation was that false claims had been submitted to federal insurance programmes such as Medicaid, the US Justice Department said. The products investigated by the US Attorney's Office in Philadelphia were the wakefulness drug Provigil (modafinil); the cancer pain treatment Actiq (oral transmuscosal fentanyl citrate); and Gabitril (tiagabine), an add-on therapy for epilepsy.